279 related articles for article (PubMed ID: 11005675)
1. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
2. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
3. Toxicodynamic evaluation of a cisplatin-chondroitin sulfate complex using a perfused kidney and human proximal tubular cells.
Zhang JS; Kadowaki D; Nonoguchi H; Hirata S; Seo H; Imai T; Suenaga A; Giam Chuang VT; Otagiri M
Ren Fail; 2011; 33(6):609-14. PubMed ID: 21631182
[TBL] [Abstract][Full Text] [Related]
4. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
6. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding.
Zhang JS; Shen-Feng MA; Suenaga A; Otagiri M
Biol Pharm Bull; 2001 Aug; 24(8):970-2. PubMed ID: 11510498
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
8. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats.
Mansour MA; Mostafa AM; Nagi MN; Khattab MM; Al-Shabanah OA
Comp Biochem Physiol C Toxicol Pharmacol; 2002 Jun; 132(2):123-8. PubMed ID: 12106889
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.
Saad SY; Najjar TA; Noreddin AM; Al-Rikabi AC
Pharmacol Res; 2001 Feb; 43(2):193-8. PubMed ID: 11243722
[TBL] [Abstract][Full Text] [Related]
12. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of royal jelly and green tea extracts effect against cisplatin-induced nephrotoxicity in mice: a comparative study.
Yapar K; Cavuşoğlu K; Oruç E; Yalçin E
J Med Food; 2009 Oct; 12(5):1136-42. PubMed ID: 19857080
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Uchino H; Matsumura Y; Negishi T; Koizumi F; Hayashi T; Honda T; Nishiyama N; Kataoka K; Naito S; Kakizoe T
Br J Cancer; 2005 Sep; 93(6):678-87. PubMed ID: 16222314
[TBL] [Abstract][Full Text] [Related]
16. Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats.
Yoshida M; Iizuka K; Terada A; Hara M; Nishijima H; Akinori ; Shimada ; Nakada K; Satoh Y; Akama Y
Tohoku J Exp Med; 2000 Aug; 191(4):209-20. PubMed ID: 11038013
[TBL] [Abstract][Full Text] [Related]
17. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
18. Relationship between age and nephrotoxicity following single low-dose cisplatin (CDDP) injection in rats.
Namikawa K; Kinsoku A; Minami T; Okazaki Y; Kadota E; Teramura K; Hashimoto S
Biol Pharm Bull; 1995 Jul; 18(7):957-62. PubMed ID: 7581250
[TBL] [Abstract][Full Text] [Related]
19. Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats.
Saad SY; Arafah MM; Najjar TA
Cancer Chemother Pharmacol; 2007 Mar; 59(4):455-60. PubMed ID: 16855841
[TBL] [Abstract][Full Text] [Related]
20. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
